Abstract The Warburg effect is ameliorated by culturing transformed cells in the presence of galactose instead of glucose as the primary carbon source. However, metabolic consequences may occur in addition to sensitizing the cells to mitochondrial toxins. The screening of pharmaceutical agents against transformed cells while using galactose must therefore be carefully evaluated. Pioglitazone is employed in clinical applications to treat type-2 diabetes but clearly has other offtarget effects. Human hepatocellular carcinoma cells (HepG2) were cultured in glucose or galactose-containing medium to investigate the role of pioglitazone on cellular bioenergetics by calorimetry and respirometry. Compared with cells cultured in 10 mM glucose, HepG2 cells cultured in the presence of 10 mM galactose showed decreased metabolic activity as measured by cellular heat flow. Interestingly, cellular heat flow increased after the addition of pioglitazone for cells cultured in glucose, but not for cells cultured in galactose. Our calorimetric data indicated that a reduction in cellular capacity for glycolysis was the mechanism responsible for the increase in sensitivity to pioglitazone, and possibly to mitochondrial toxins in general, for cells cultured in galactose. Furthermore, oxygen consumption rates were decreased after the addition of pioglitazone to cells grown in glucose but remained unchanged for cells grown in the presence of galactose. We have demonstrated that pioglitazone induces a reduction in mitochondrial activity that is partially compensated via an increase in glycolysis in the presence of glucose.
Introduction
Thiazolidinediones (TZD) are effective insulin sensitizers used to treat type-2 diabetes and have been shown to reduce the risk of conversion from impaired glucose tolerance to type-2 diabetes (Day 1999; DeFronzo et al. 2011) . Most of the antidiabetic properties of TZDs are believed to be mediated through changes in gene expression patterns after their binding to the nuclear peroxisome proliferator-activated receptor (PPAR)-γ (Cariou et al. 2012) . However, mounting evidence indicates that at least part of TZD action is independent of the PPAR-γ-mediated transactivation and transrepression of target genes (Feinstein et al. 2005) . Pleiotropic mechanisms in addition to PPAR-γ binding appear to be crucial for the broad pharmacological profile of TZDs and potentially include several effects on mitochondria, including inhibition of the respiratory complex I (Brunmair et al. 2004) , inhibition of the mitochondrial pyruvate carrier (Divakaruni et al. 2013) , and binding to CISD1 (Colca et al. 2004; Geldenhuys et al. 2014; Paddock et al. 2007) .
First described nearly 60 years ago by Otto Warburg, highly proliferating cancer cells are often characterized by a shift in energy production from oxidative phosphorylation to glycolysis, despite the presence of saturating concentrations of oxygen (Baerobic glycolysis^; Kim et al. 2006; Vander Heiden et al. 2009; Warburg 1956 ). In some cases, mitochondrial respiration rates can be rescued if glucose levels are low, and suppression in respiration by a high glucose concentration is a phenomenon known as the Crabtree effect (Diaz-Ruiz et al. 2011; Ibsen 1961) . For example, substitution of the primary energy substrate glucose by galactose increases mitochondrial activity in several models, including adenocarcinoma (HeLa) and hepatocellular carcinoma (HepG2) cells, and sensitizes HepG2 cells to some mitochondrial toxins (Marroquin et al. 2007; Rossignol et al. 2004) . The reason for the increase in mitochondrial respiration in the presence of galactose is still poorly understood. Glucose and galactose metabolism yields equivalent amounts of ATP, and both sugars are equally good as energy sources, but the shift towards respiration might be attributable to flux limitations through the Leloir pathway (Frey 1996; Petry et al. 1998) , since galactose enters glycolysis at a lower rate than glucose (Bustamante et al. 1977) . However, in the presence of galactose and glutamine, HeLa cells use glutamine to provide about 98% of the ATP used for cell growth (Reitzer et al. 1979) .
A non-invasive method for directly measuring the metabolic response of cells to drugs and changes in substrate availability involves the simultaneous measurement of heat flow and oxygen flux (Gnaiger et al. 1990 ). This approach not only yields baseline estimates of energy flow, but can also be used to evaluate the contribution of anaerobic pathways (e.g., glycolysis) to overall cellular energy homeostasis (Guan et al. 1999; Menze et al. 2010) . We have found a pronounced increase in chemically uncoupled cellular respiration, but a depression in heat dissipation for cells cultured in presence of galactose compared with glucose-cultured cells, indicating a shift in metabolic poise from glycolysis to respiration.
We have investigated the effect of galactose and pioglitazone on the bioenergetics and growth of HepG2 cells. Our results demonstrate that (1) galactose treatment shifts metabolic poise from glycolysis to oxidative phosphorylation, (2) pioglitazone treatment inhibits oxidative phosphorylation, (3) in the presence of high glucose concentrations, cells compensate for pioglitazone-induced reductions in respiration via an increase in glycolysis, and (4) a significant reduction in cell proliferation after addition of pioglitazone is observed in the presence of glucose but is absent if cells are dependent on galactose as a carbon source. Furthermore, increased metabolic activity induced by pioglitazone is abolished in galactosebased medium. This study demonstrates that the measurement of cellular proliferation as an indicator of drug efficacy in the galactose-utilization model of cell culture can be misleading if a more detailed technique, such as calorespirometry, is not also performed.
Materials and methods
All chemicals used for respirometry and solution preparations were of the highest grade and purchased from Sigma-Aldrich (St. Louis, Mo., USA) or Fisher Scientific (Fair Lawn, N.J., USA). Human hepatocellular carcinoma cells (HepG2) were cultured in glucose free DMEM (Dulbecco's modified Eagle medium) supplemented with either 10 mM D-galactose or glucose following the protocol described in Stokich et al. (2014) . Microcalorimetry was performed following the procedures detailed in Menze et al. (2010) , and respirometry measurements were based on the methods described in Stokich et al. (2014) . Detailed descriptions of the employed methods are provided in the Electronic supplemental material.
Results

Impact of pioglitazone on respiration of HepG2 cells
Significant reductions in oxygen flux by about 13% were observed after the addition of 60 μM pioglitazone to cells respiring in cell culture medium containing 10 mM glucose (n = 6, P ≤ 0.05; Fig. 1a ). A more pronounced inhibitory effect of pioglitazone on cellular respiration was observed if oxygen flux was stimulated via the addition of trifluoromethoxycarbonylcyanide-phenylhydrazone (FCCP), and routine respiration rates in control cells increased nearly three-fold in the presence of this potent chemical uncoupler. After the addition of pioglitazone, the uncoupled respiration rate was significantly inhibited by about 30% (n = 6, P ≤ 0.05; Fig. 1a ). Moreover, pioglitazone acted as a weak chemical uncoupler in intact cells, and proton leak respiration rates in the presence of the F 0 F 1 -ATPase inhibitor oligomycin (LEAK o ) were significantly increased when pioglitazone was present (n = 6, P ≤ 0.05; Fig. 1a ). This significant mitochondrial uncoupling effect of pioglitazone was a common finding throughout this study, but we did not observe statistically significant increases in oxygen consumption rates of HepG2 cultured in galactose for two weeks compared with glucose controls (n = 6, P > 0.05; Fig. 1b ). However, maximal uncoupled respiration (FCCP) was significantly higher for cells cultured in galactose, and the addition of pioglitazone did not reduce uncoupled respiration rates as observed for cells cultured in glucose. Furthermore, no increase in LEAK o respiration was observed in the presence of pioglitazone (n = 6, Fig. 1b) .
In order to elucidate the action(s) of pioglitazone on the oxidative phosphorylation system (OXPHOS) in more detail, HepG2 cells were permeabilized with digitonin, and saturating levels of substrates were added to the sucrose-based respiration medium. Two different titration protocols promoting electron entry into the electron transport chain (ETS) via FADH 2 or via NADH and FADH 2 were employed. In the first titration protocol, oxygen flux fueled by succinate dehydrogenase (complex II) activity was measured in the presence of the NADH:ubiquinone oxidoreductase (complex I) inhibitor rotenone and saturating levels of succinate. When using succinate as the complex II substrate, the addition of pioglitazone to permeabilized cells significantly stimulated oxygen flux compared with untreated control (n = 6, P ≤ 0.05; Fig. 2a, b) . For cells cultured in glucose medium, respiration rates after the addition of ADP did not differ between the pioglitazonetreated and control cells, demonstrating that pioglitazone does not cause significant reductions in the activities of succinate dehydrogenase or the mitochondrial phosphorylation system (Fig. 2a) . As with intact cells, a significant uncoupling effect of pioglitazone was observed after the addition of oligomycin (Fig. 2a, b) . Interestingly, pioglitazone reduced OXPHOS rates in cells cultured in galactose medium (Fig. 2b) .
We next investigated the effect of pioglitazone on complex I activity followed by the concurrent presence of NADH-and FADH 2 -generating substrates (Fig. 3a, b) . A combination of malate, glutamate, and pyruvate was added to permeabilized cells to stimulate NADH production by mitochondrial Fig. 2 Respiration rates of HepG2 cells cultured in glucose-based (a) or galactose-based (b) medium for two weeks prior to respirometry. Oxygen flux is shown for control cells (black bars) and in the presence of 60 μM pioglitazone (gray bars). Respiration rates of cells permeabilized with digitonin (Dig) wecre recorded in the presence of the complex I inhibitor rotenone (Rot) and the substrate succinate (Succ). OXPHOS rates were measured after the addition of ADP (ADP), and leak respiration was recorded after inhibition of the F 0 F 1 -ATPase with oligomycin (Olig). AMA-A Antimycin A. *Statistically significant differences after addition of pioglitazone. # Statistically significant differences between cells cultured in glucose-based or galactose-based medium (n = 6, ± SE) Fig. 1 Respiration rates of HepG2 cells cultured in glucose-based (a) or galactose-based (b) medium for two weeks prior to respirometry. Oxygen flux is shown for control cells (black bars) and in presence of 60 μM pioglitazone (gray bars). Uncoupled respiration was induced by titrations with trifluoromethoxycarbonyl-cyanide-phenylhydrazone (FCCP), and leak respiration was recorded after inhibition of the F 0 F 1 -ATPase with oligomycin (Olig). *Statistically significant differences after addition of pioglitazone. # Statistically significant differences between cells cultured in glucose-based or galactose-based medium (n = 6, ± SE) dehydrogenases. In contrast to our results with succinate, no increase in oxygen flux was observed in the presence of pioglitazone compared with untreated controls indicating an inhibition of NADH-poised respiration below an activity needed to establish a proton-motive force (Δp) large enough to observe the uncoupling effect of pioglitazone (Fig. 3a) . The same effect was observed for cells grown in galactose-based medium (Fig. 3b) . A severe inhibition in complex I activity was confirmed after the addition of ADP. In the presence of pioglitazone, ADP failed to stimulate oxygen flux, but similar to our results with succinate alone, respiration could be rescued by the addition of succinate. LEAK o respiration after the addition of oligomycin was elevated by 63% in cells treated with pioglitazone if succinate was present and was slightly higher in cells grown in galactose-based medium (n = 6, p ≤ 0.05; Fig. 3a, b) .
Pioglitazone increased heat dissipation in presence of glucose but not galactose
Although the exact mechanism is unknown, some immortalized cells will shift energy production from glycolysis towards mitochondrial respiration in medium supplemented with galactose instead of glucose. In contrast to respirometry, calorimetry captures the overall metabolic activity including changes in glycolytic activity. HepG2 cells cultured in glucose-containing medium or galactose-containing medium were treated with 60 μM pioglitazone, and heat dissipation was monitored every 30 min for 2 h. During this period, heat dissipation dropped for galactose-cultured cells, but not for cells measured in glucose-containing medium (Table 1) . However, after 30 min of exposure to pioglitazone, heat dissipation of HepG2 cells in glucose-containing medium was increased by about 15%, but no increase was observed for galactose-treated cells. Furthermore, overall heat output was about 17% lower for cells cultured in the presence of galactose compared with cells in glucose-containing medium (Table 1) . Heat dissipation data demonstrated an overall reduction in metabolic activity and indicated that cells cultured in galactose-based medium might be characterized by an overall decrease in cellular proliferation. This was confirmed by following cellular growth, and the fold-increase in cells per 24-h period decreased by about 40% if cells were grown in galactose-based medium compared with glucose-based medium. A significant drop in proliferation rate was also observed after the addition of pioglitazone to cells grown in glucosebased medium. However, no additional decrease in proliferation was observed after the addition of pioglitazone to cells grown in galactose-based medium (Table 2) .
Discussion
We have investigated the consequences of shifting the metabolic poise of HepG2 cells from glycolysis to oxidative phosphorylation on pioglitazone-induced changes in metabolic activity. An increase in mitochondrial capacity was achieved by substituting glucose for galactose in the cell culture medium for two weeks. We found that pioglitazone reduced cellular respiration and increased glycolytic flux in cells cultured in the presence of glucose, but not in cells cultured in galactosebased medium. Furthermore, pioglitazone severely inhibited complex I respiration in permeabilized cells, but the overall capacity for oxidative phosphorylation could be largely rescued by FADH 2 production in the presence of succinate. This Fig. 3 Respiration rates of HepG2 cells cultured in glucose-based (a) or galactose-based (b) medium for 2 weeks prior to respirometry. Oxygen flux is shown for control cells (black bars) and in the presence of 60 μM pioglitazone (gray bars). Respiration rates of cells permeabilized with digitonin (Dig) were recorded in the presence of NADH-generating substrates (MGP), and OXPHOS rates were measured after the addition of ADP (ADP). Convergent electron entry into the ubiquinone pool was initiated by the addition of succinate (Succ), and leak respiration was recorded after the inhibition of the F 0 F 1 -ATPase with oligomycin (Olig). AMA-A Antimycin A. *Statistically significant differences after addition of pioglitazone. # Statistically significant differences between cells cultured in glucose or galactose-containing medium (n = 6, ± SE) capacity for compensation by complex II might be the reason for a less pronounced toxicity as might be expected based on the severe inhibition of complex I activity.
Pioglitazone is well known to alter mitochondrial bioenergetics. Acute effects of pioglitazone on primary hepatocytes and isolated mitochondria show reductions in cellular and complex-I-fueled respiration rates (Brunmair et al. 2004; Sanz et al. 2011) . Enzymatic assays on isolated mitochondrial complexes from mouse liver have demonstrated decreases in complex I and III activity with increasing pioglitazone concentrations, and the drug has been shown to disassemble complex I into four distinct subcomplexes (Garcia-Ruiz et al. 2013) .
We were interested in the effect of pioglitazone on highly proliferating HepG2 cells under in vivo conditions, since the relatively low toxicity of pioglitazone seemed difficult to explain based on the pronounced inhibition of complex I. We were especially interested to determine the effects of using the galactose model of cell culture on cellular energy flow in the presence of the known mitochondrial toxin pioglitazone. In the absence of anaerobic pathways, the ratio of heat flux to oxygen flux (CR-ratio) should be in the range of the theoretical oxycaloric equivalent (−430 to −480 kJ mol O 2 ; Gnaiger et al. 1990 ). The CR-ratio for HepG2 cells grown in glucose-based medium was elevated to −520 kJ/mol O 2 indicating anaerobic contributions to energy production. In response to 60 μM pioglitazone, an increase in the CR-ratio to −720 kJ/mol O 2 was observed, demonstrating an increase in glycolytic activity. Reductions in mitochondrial energy production attributable to the inhibition of respiration by pioglitazone were apparently being counteracted by an increase in glycolytic flux. This increase in glycolytic flux was absent for cells cultured in galactose-based medium. In the presence of galactose, cells were less glycolytically poised with a CR-ratio of −470 kJ/mol O 2 , and no increase in the CR-ratio was observed in response to pioglitazone.
Although galactose treatment of immortalized cells increases the oxidative capacity of mitochondria (Marroquin et al. 2007 ) and, indeed, rescues cells partially from the Warburg effect, sensitization to mitochondrial toxins may be obscured. We did not observe a reduction in proliferation rates after pioglitazone addition to cells cultured in galactose. Only by combining proliferation studies with respirometry and calorimetry were we able to gain a further insight into the mechanism of action of pioglitazone. Therefore, caution is warranted in the interpretation of toxicity and efficacy studies of drug molecules in galactose-based culture studies in the absence of a thorough metabolic characterization of the treated cells. 
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